AGILeBiotics is developing of novel antibiotics to treat multi-drug resistant (MDR) Gram-negative infections. The main focus is to find new antibiotic candidates active against carbepenem-resistant Enterobacteriaceae (CRE). In addition, AGILeBiotics is motivated in finding novel treatment options for MDR tuberculosis and cystic fibrosis.